HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice
Immunity · 2026
DOI: 10.1016/j.immuni.2026.01.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2026. Verfasst von Nicolas M S Galvez und 24 weiteren Autor:innen. Beteiligte Einrichtung: Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Dependovirus, HIV Infections, Immunotherapy, HIV Antibodies. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, Charles H Hood Foundation.
Abstract (Originalsprache)
Broadly neutralizing antibodies (bNAbs) have shown promise for the prevention and treatment of HIV. Potency and breadth measured in vitro are often used as predictors of clinical potential; however, human studies demonstrate that the clinical efficacy of bNAbs can be undermined by both preexisting and de novo resistance. Here, we found that HIV-infected humanized mice receiving bNAbs delivered via adeno-associated virus (AAV) as vectored immunotherapy (VIT) could be used to identify antibody escape paths, which were largely conserved for each bNAb. Path selection and consequent therapeutic success were driven by the fitness cost and resistance benefit of emerging mutations. Applying this framework, we independently modulated bNAb resistance or the fitness cost of escape mutants, resulting in the enhanced efficacy of VIT. This escape-path analysis successfully explains the therapeutic efficacy of bNAbs and enables a tractable means of quantifying and comparing the potential for viral escape from therapeutics in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases and National Institutes of Health, Bethesda, MD 20892, USA.
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- Charles H Hood Foundation
- Massachusetts General Hospital
- National Institute of Allergy and Infectious Diseases
- Gilead Research Scholars Program
- Centers for Disease Control and Prevention
- National Institute on Drug Abuse
Zitieren
APA
Galvez, N. M. S., Nitido, A. D., Yoo, S. B., Cao, Y., Deal, C. E., Boutros, C. L., MacDonald, S. W., Soto Albrecht, Y. E., Lam, E. C., Sheehan, M. L., Parsons, D., Lin, A. Z., Deymier, M. J., Brady, J. M., Moon, B., Bullock, C. B., Tanno, S., Pegu, A., Chen, X., …, & Balazs, A. B. (2026). HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. Immunity. https://doi.org/10.1016/j.immuni.2026.01.031
Vancouver
Galvez NMS, Nitido AD, Yoo SB, Cao Y, Deal CE, Boutros CL, et al. HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. Immunity. 2026. doi:10.1016/j.immuni.2026.01.031
BibTeX
@article{Galvez2026,
author = {Galvez, Nicolas M S and Nitido, Adam D and Yoo, Seo Bin and Cao, Yi and Deal, Cailin E and Boutros, Christine L and MacDonald, Scott W and Soto Albrecht, Yentli E and Lam, Evan C and Sheehan, Maegan L and Parsons, Dylan and Lin, Allen Z and Deymier, Martin J and Brady, Jacqueline M and Moon, Benjamin and Bullock, Christopher B and Tanno, Serah and Pegu, Amarendra and Chen, Xuejun and Liu, Cuiping and Koup, Richard A and Mascola, John R and Vrbanac, Vladimir D and Lingwood, Daniel and Balazs, Alejandro B},
title = {HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice},
journal = {Immunity},
year = {2026},
doi = {10.1016/j.immuni.2026.01.031}
}
EUVIMED